Millennium Management
CNTX icon

Millennium Management’s Context Therapeutics CNTX Stock Holding History

Millennium Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.73M Sell
1,424,374
-1,176,842
-45% -$2.75M ﹤0.01% 3263
2025
Q4 		$3.82M Buy
+2,601,216
New +$3.04M ﹤0.01% 3300
2025
Q3 		– Sell
-17,067
Closed -$11.2K – 6077
2025
Q2 		$11.2K Sell
17,067
-31,604
-65% -$22.7K ﹤0.01% 5715
2025
Q1 		$29.8K Sell
48,671
-130,047
-73% -$113K ﹤0.01% 5591
2024
Q4 		$188K Buy
178,718
+34,835
+24% +$60.3K ﹤0.01% 5330
2024
Q3 		$282K Buy
+143,883
New +$319K ﹤0.01% 5229

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management's CNTX Position: Q1 2026 in Review

Millennium Management reduced its Context Therapeutics (CNTX) stake by 45% in Q1 2026, selling an estimated $2.75M and leaving 1,424,374 shares worth $3.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3263.

Millennium Management first reported a position in CNTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $3.82M in Q4 2025. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Millennium Management held 1,424,374 shares of Context Therapeutics worth $3.73M as of Q1 2026.
  • Millennium Management sold 1,176,842 Context Therapeutics shares in Q1 2026, an estimated $2.75M.
  • Context Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3263 holding.
  • Millennium Management first reported a position in Context Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Millennium Management's Context Therapeutics position peaked at $3.82M in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.